Compare Immuno-Biological Laboratories Co., Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 6.24%
- The company has been able to generate a Return on Equity (avg) of 6.24% signifying low profitability per unit of shareholders funds
2
Healthy long term growth as Operating profit has grown by an annual rate 20.91%
3
With a growth in Net Profit of 32.11%, the company declared Very Positive results in Dec 25
4
With ROE of 20.33%, it has a expensive valuation with a 7.79 Price to Book Value
5
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 12,863 Million (Small Cap)
38.00
NA
0.00%
-0.40
20.33%
7.30
Revenue and Profits:
Net Sales:
257 Million
(Quarterly Results - Dec 2025)
Net Profit:
107 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.07%
0%
-24.07%
6 Months
146.62%
0%
146.62%
1 Year
180.34%
0%
180.34%
2 Years
177.38%
0%
177.38%
3 Years
280.29%
0%
280.29%
4 Years
321.86%
0%
321.86%
5 Years
152.79%
0%
152.79%
Immuno-Biological Laboratories Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.40%
EBIT Growth (5y)
20.91%
EBIT to Interest (avg)
-8.88
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
0.57
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.25%
ROE (avg)
6.24%
Valuation key factors
Factor
Value
P/E Ratio
38
Industry P/E
Price to Book Value
7.79
EV to EBIT
42.27
EV to EBITDA
39.89
EV to Capital Employed
12.36
EV to Sales
12.62
PEG Ratio
1.93
Dividend Yield
NA
ROCE (Latest)
29.24%
ROE (Latest)
20.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
256.70
274.00
-6.31%
Operating Profit (PBDIT) excl Other Income
86.00
92.30
-6.83%
Interest
0.30
0.30
Exceptional Items
0.20
0.00
Consolidate Net Profit
106.60
80.70
32.09%
Operating Profit Margin (Excl OI)
316.60%
320.10%
-0.35%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -6.31% vs 29.55% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 32.09% vs 32.51% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
969.50
816.70
18.71%
Operating Profit (PBDIT) excl Other Income
224.80
113.30
98.41%
Interest
1.30
1.10
18.18%
Exceptional Items
0.40
-0.50
180.00%
Consolidate Net Profit
249.00
186.70
33.37%
Operating Profit Margin (Excl OI)
215.90%
135.90%
8.00%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 18.71% vs 2.78% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 33.37% vs 164.45% in Mar 2024
About Immuno-Biological Laboratories Co., Ltd. 
Immuno-Biological Laboratories Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






